Radiopharmaceutical M&A raises unique challenges. We outline how supply chain, regulation and deal structuring shape execution and value.

Radiopharmaceuticals are at the forefront of medical innovation. As demand for personalised and targeted therapies grows, so does investor interest in the sector. At the same time, the distinctive characteristics of radiopharmaceuticals introduce a risk profile that differs fundamentally from traditional pharmaceuticals, with material implications for mergers and acquisitions.

In this post, we outline the key dynamics shaping this niche, how those dynamics translate into execution risks in transactions, and we consider how investors can navigate these risks through a combination of diligence, structuring and contractual tools.

How does the special nature of radiopharmaceuticals affect transactions?

1. Supply chain

The radiopharmaceutical supply chain is defined by speed and interdependence. For many products, less than a week passes between sourcing a radioactive isotope in one part of the world, processing it in a reactor, pharmaceutical manufacturing, regulated transportation, and administering a finished medicinal product to a patient in another.

Because isotopes cannot be stockpiled, the supply chain consists of a series of tightly linked, time‑critical stages, each vulnerable to disruption. Tariff changes, export restrictions, sanctions and transport limitations can all have disproportionate effects on manufacturing continuity, patient access and revenues.

From a transactional perspective, this fragility has two important consequences. First, diligence must identify not only legal compliance but also points of operational concentration and dependency. Second, transaction documents must reflect the reality that even minor interruptions can have outsized commercial consequences and the associated risks require more than standard remedies to be cured or mitigated.

2. Regulatory complexity

Radiopharmaceuticals sit at the intersection of pharmaceutical and nuclear regulation, resulting in a complex compliance environment characterised by dual oversight. In practice, this often means parallel and time‑consuming regulatory approval processes.

The EU has made progress towards harmonisation, but national rules continue to apply in key areas. Beyond Europe, regulatory fragmentation is the norm.

For transactions, this means that regulatory diligence goes beyond confirming formal compliance. Investors need a nuanced understanding of how pharmaceutical and nuclear requirements interact in the target’s specific operating jurisdictions, and how regulatory approvals, inspections or enforcement action in one area might affect the wider value chain. This complexity necessitates customised documentation and, in some cases, tailored deal structures.

What trends are shaping transactions?

This environment is driving increased reliance on manufacturing partnerships and CDMOs, as innovation‑led businesses seek access to reactor capacity, processing expertise and compliant infrastructure. At the same time, companies and investors are reassessing which parts of the value chain they are required to own and where strategic partnerships are more appropriate.

Legally, we are witnessing growing demand for tailored transactions with bespoke documentation. The allocation of assets, risks and control across different stages of the supply chain is a central deal consideration, rather than a post‑closing operational issue.

How can risks be managed?

Successful deals will balance a combination of rigorous diligence, thoughtful transaction structuring and realistic risk allocation, including the following.

1. Areas requiring additional due diligence

Given the inherently cross‑border nature of supply chains, diligence should assess exposure to shifting international trade rules and geopolitical constraints. This includes the origin of isotopes, APIs and excipients, and the impact of tariffs, export controls or import limitations.

Key elements of the supply chain include:

o  Nuclear processing. Limited reactor capacity, particularly in Europe, constrains production growth. While expansion is underway, progress is shaped by regulatory complexity, long approval timelines and significant capital investment. Growth plans may appear robust on paper, but deal risk often turns on the security of additional capacity. This affects contractual access arrangements and de-risking models.

o  Molecule preparation. Combining isotopes with non‑radioactive molecules requires authorisation from both pharmaceutical and radiation regulators. GMP certification is essential, and cross‑border inspections can be affected by geopolitical factors, creating approval and continuity risk. Seemingly minor dependencies can be decisive, for example where batch release is tied to a specific qualified person or external laboratory, or where lead times leave no practical recovery window for deviations. For all these areas contracts, policies and procedures must be in place.

o  Logistics. With half‑lives of six to ten days for certain key isotopes, reliable transport is critical. Airspace closures or customs delays can halt supply entirely, with no mitigation through stockpiling. Diligence therefore focuses less on generic force majeure drafting and more on whether disruption can realistically be managed through workable contingencies or contractual remedies.

o  Patient administration. The “last mile” requires specialised facilities and trained personnel, with significant variation between countries in infrastructure and regulatory readiness.

In practice, diligence for these deals is less about confirming compliance at a point in time and more about stress‑testing how the business operates under adverse conditions and how flexibly it works in the event of future changes.

2. Deal structure

Extreme‑risk provisions such as force majeure, hardship and material adverse change clauses are increasingly scrutinised, particularly in manufacturing and supply agreements. In the M&A context, these provisions require careful calibration to avoid unintended price‑adjustment mechanisms or embedded exit rights.

Contractual drafting alone is rarely sufficient. Where risks are systemic or existential, investors often turn to structural solutions, such as staged acquisitions, earn‑outs tied to regulatory or manufacturing milestones, or carving out particularly high‑risk assets or activities from the initial transaction perimeter. Attractive arrangements to retain key personnel are often crucial.

3. Mitigating regulatory risk beyond transaction documentation

Dual oversight by pharmaceutical and nuclear regulators increases the likelihood that regulatory or operational failures may result in liabilities exceeding any realistic contractual cap. As a result, reliance on indemnities alone is unlikely to provide adequate protection.

Strong internal governance and compliance frameworks therefore play a central role in risk management and avoiding allegations of organisational failure, with transaction documentation used to address residual gaps. Appropriately scoped D&O insurance and proactive regulatory engagement should complement contractual protections, rather than replace them. Tailored business interruption insurance as well as political risk coverage may need to be in place.

4. Antitrust considerations

Radiopharmaceutical supply chains are naturally concentrated and often lack flexibility. Transactional risk can arise where long‑term supply arrangements or contractual terms exacerbate imbalances through pricing mechanisms, exclusivity, vendor lock‑ins or switching barriers.

Key antitrust considerations include access to critical infrastructure, refusal‑to‑supply risks, non‑discrimination obligations and vertical restrictions, all of which require close attention in both deal structuring and post‑closing integration.

5. Commercial arrangements

Radiopharma CDMOs are particularly exposed to supply‑chain disruption, as their operations are tailored to specific clients and time‑critical products. Delays, trade barriers or regulatory intervention can bring production to an immediate standstill, while diversification options are often limited.

In response, market practice is evolving to focus on contractual mechanisms that seek to influence behaviour rather than simply allocate liability. While such protections are not always achievable in a concentrated supplier market, their availability can materially affect valuation and integration planning.

6. Intellectual property and data protection

Radiopharmaceutical products and manufacturing processes are inherently innovative and frequently rely on know-how. Process know‑how and tech‑transfer packages can be decisive.

This heightens diligence risk and places particular emphasis on ensuring the completeness of IP transfers and the robustness of contractual protections designed to preserve value in an M&A context. Protection of data and internal access to technology require classification and sophisticated usage procedures.

Where next?

Successful transactions start by understanding how risk moves from sourcing through reactor and manufacturing to market. In our experience advising on transactions in this sector, value is maximised through focused diligence, clear deal structure, forward-looking contract design and strong organisational governance.